Printer Friendly

CYTRX SAYS RHEOTHRX UNDER CONSIDERATION FOR ISIS-5 TRIAL

 ATLANTA, Sept. 20 /PRNewswire/ -- Scrip has reported that the novel antithrombotic compound, RheothRx(R), licensed by CytRx Corporation (NASDAQ: CYTR) to Burroughs Wellcome, is under consideration by the ISIS study group (International Study of Infarct Survival) for inclusion in its fifth myocardial infarction trial.
 Previous ISIS trials have been pivotal in demonstrating the efficacy of thrombolytic agents and beta-blockers and have altered the course of heart attack therapy. ISIS trials typically include 40,000 to 60,000 patients enrolled worldwide. RheothRx is being developed by Burroughs Wellcome as part of its worldwide licensing agreement with CytRx.
 Prior to the final decision, the ISIS Steering Committee will evaluate data from a large, international, Phase III trial of RheothRx in myocardial infarction patients which will begin in the next few months. Scrip reported that ISIS-5 is expected to commence in 1995.
 Jack J. Luchese, CytRx president and chief executive officer, commented on the report: "We are extremely pleased and encouraged that RheothRx is under consideration for this important international study. ISIS-5 will be an ideal setting to demonstrate the therapeutic benefits of RheothRx on a large-scale basis."
 CytRx Corporation is engaged in the research and development of critical care pharmaceutical products for the treatment of vascular and infectious diseases, burns and cancer. Vaxcel(TM), a CytRx subsidiary, is developing an advanced adjuvant system for human and veterinary use. CytRx's Vetlife(TM) subsidiary is developing feed additives to enhance growth in feed animals.
 -0- 9/20/93
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR)


CO: CytRx Corporation ST: Georgia IN: MTC SU:

BN-CF -- AT006 -- 3544 09/20/93 10:12 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 20, 1993
Words:268
Previous Article:DIGITAL COMMUNICATIONS CONSIDERING ACQUISITION PROPOSAL
Next Article:SYNCOR TO PROVIDE EDUCATIONAL SITE FOR PURDUE UNIVERSITY PHARMACY STUDENTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters